Shigeyuki Matsui

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. ncbi Creutzfeldt-Jakob disease and cadaveric dura mater grafts in Japan: an updated analysis of incubation time
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Neuroepidemiology 24:22-5. 2005
  2. ncbi Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto, Japan
    Curr Drug Saf 1:135-41. 2006
  3. ncbi Sample size calculations based on ranking and selection in microarray experiments
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biometrics 64:217-26. 2008
  4. ncbi Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto, Japan
    Stat Med 27:1106-20. 2008
  5. ncbi Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, Graduate School of Public Health, Kyoto University, Kyotom, Japan
    Bioinformatics 23:732-8. 2007
  6. ncbi Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto 606 8501, Japan
    BMC Bioinformatics 7:156. 2006
  7. ncbi Stratified analysis in randomized trials with noncompliance
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Biometrics 61:816-23. 2005
  8. ncbi Sample size calculations for comparative clinical trials with over-dispersed Poisson process data
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Stat Med 24:1339-56. 2005
  9. ncbi Analysis of times to repeated events in two-arm randomized trials with noncompliance and dependent censoring
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Biometrics 60:965-76. 2004
  10. ncbi P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer
    Masaaki Ito
    Department of Urology and Pharmacoepidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    J Urol 178:1073-9. 2007

Collaborators

Detail Information

Publications21

  1. ncbi Creutzfeldt-Jakob disease and cadaveric dura mater grafts in Japan: an updated analysis of incubation time
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Neuroepidemiology 24:22-5. 2005
    ..These results suggest that some host factors may have an influence on the incubation time of the disease...
  2. ncbi Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto, Japan
    Curr Drug Saf 1:135-41. 2006
    ..The evaluation of stability and reproducibility of the results of statistical analysis are claimed to reduce chance that false positive findings are subject to further investigation in subsequent studies...
  3. ncbi Sample size calculations based on ranking and selection in microarray experiments
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biometrics 64:217-26. 2008
    ..We provide strategies for conservative designs to cope with issues of unknown number of informative genes and unknown correlation structure across genes. Application of the formulae to a clinical study for multiple myeloma is given...
  4. ncbi Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto, Japan
    Stat Med 27:1106-20. 2008
    ..Application of such clustering to the data set from a clinical study for patients with multiple myeloma and associated microarrays is given...
  5. ncbi Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, Graduate School of Public Health, Kyoto University, Kyotom, Japan
    Bioinformatics 23:732-8. 2007
    ..Although many class comparisons concerned only a single phenotype, simultaneous assessment of the relationship between gene expression and multiple phenotypes would be warranted to better understand the underlying biological structure...
  6. ncbi Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto 606 8501, Japan
    BMC Bioinformatics 7:156. 2006
    ..The primary analytical task in such studies is to select a small fraction of relevant genes, typically from a list of significant genes, for further investigation in subsequent studies...
  7. ncbi Stratified analysis in randomized trials with noncompliance
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Biometrics 61:816-23. 2005
    ..Application to a field trial for coronary heart disease is provided...
  8. ncbi Sample size calculations for comparative clinical trials with over-dispersed Poisson process data
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Stat Med 24:1339-56. 2005
    ..This formula can accommodate time heterogeneity, inter-patient heterogeneity in event rate, and also, time-varying treatment effects. An application of the formula to a trial for chronic granulomatous disease is provided...
  9. ncbi Analysis of times to repeated events in two-arm randomized trials with noncompliance and dependent censoring
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto 606 8501, Japan
    Biometrics 60:965-76. 2004
    ..A simulation study is conducted to evaluate the performance of the developed methods. An illustration of the methods using data from an acute myeloid leukemia trial is provided...
  10. ncbi P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer
    Masaaki Ito
    Department of Urology and Pharmacoepidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    J Urol 178:1073-9. 2007
    ..We developed molecular markers for predicting intravesical recurrence of superficial bladder transitional cell carcinoma using oligo-microarray analysis...
  11. ncbi Bayesian ranking and selection methods using hierarchical mixture models in microarray studies
    Hisashi Noma
    Department of Biostatistics, Kyoto University School of Public Health, Yoshida konoe cho, Sakyo ku, Kyoto, Japan
    Biostatistics 11:281-9. 2010
    ..The accuracy of our ranking methods is compared with that of conventional methods through simulation studies. An application to a clinical study for breast cancer is provided...
  12. ncbi Sample size calculations for controlling the distribution of false discovery proportion in microarray experiments
    Tomonori Oura
    Department of Biostatistics, Kyoto University School of Public Health, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biostatistics 10:694-705. 2009
    ..Gene clustering is proposed to identify gene blocks using historical data sets. The adequacy of the procedure is demonstrated using simulated data sets. An application to a clinical study for lymphoma is also provided...
  13. ncbi The optimal discovery procedure in multiple significance testing: an empirical Bayes approach
    Hisashi Noma
    Department of Biostatistics, Kyoto University School of Public Health, Yoshidakonoe cho, Sakyo ku, Kyoto, 606 8501, Japan
    Stat Med 31:165-76. 2012
    ..Simulations and applications to clinical studies of leukemia and breast cancer demonstrated that our empirical Bayes method achieved theoretical optimality and performed well in comparison with existing multiple testing procedures...
  14. ncbi Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan
    Mina Tsubouchi
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyoku, Kyoto 606 8501, Japan
    Regen Med 3:497-504. 2008
    ..To identify which factors are important barriers to effective collaboration between Japanese academia and industry in the field of regenerative medicine...
  15. ncbi Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
    Noriomi Matsumura
    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Cancer Sci 101:2658-63. 2010
    ..This report demonstrates a method to utilize genome-wide information to facilitate translational research for treatments against less common subtypes of cancers...
  16. ncbi Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study
    Koji Yoshimura
    Department of Urology, Translational Research Center, Graduate School of Medicine Kyoto University, Sakyo ku, Kyoto, Japan
    Int J Urol 17:548-54. 2010
    ..The aim of this study was to assess the efficacy and safety of two different types of medical mushrooms in patients with prostate cancer in Japan...
  17. ncbi Prognostic factor analysis for plaque psoriasis
    Rie Sakai
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Kyoto, Japan
    Dermatology 211:103-6. 2005
    ..Little is known about the long-term prognostic factors which affect clinical outcomes after the diagnosis of psoriasis...
  18. ncbi Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm
    Hiromitsu Negoro
    Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo, Kyoto 606 8507, Japan
    Nat Commun 3:809. 2012
    ..Therefore, circadian oscillation of connexin43 is associated with the biological clock and contributes to diurnal changes in bladder capacity, which avoids disturbance of sleep by micturition...
  19. ncbi Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy
    Daisuke Watanabe
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
    N Engl J Med 353:782-92. 2005
    ..CONCLUSIONS: Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy...
  20. ncbi Estimating effect sizes of differentially expressed genes for power and sample-size assessments in microarray experiments
    Shigeyuki Matsui
    Department of Data Science, The Institute of Statistical Mathematics, 10 3 Midori cho, Tachikawa, Tokyo 190 8562, Japan
    Biometrics 67:1225-35. 2011
    ..Applications to two real datasets from cancer clinical studies are provided...
  21. ncbi Overview of the clinical application of regenerative medicine products in Japan
    Mina Tsubouchi
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Health Policy 88:62-72. 2008
    ..To identify barriers to the clinical application of regenerative medicine products (RMPs) in Japan...